Clinical Trial Update: Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) [Phase 3]

View source ↗

Summary

This Phase 3 trial (BENEFIT) evaluated belatacept as first-line immunosuppression in kidney transplant recipients, with results posted after completion in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• belatacept (belatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Kidney Transplantation, Chronic Kidney Failure | Phase 3 | Status: COMPLETED | Results posted: 2016-08-19